HIV-1 DNA Decay Dynamics in Blood During More Than a Decade of Suppressive Antiretroviral Therapy. (29th July 2014)
- Record Type:
- Journal Article
- Title:
- HIV-1 DNA Decay Dynamics in Blood During More Than a Decade of Suppressive Antiretroviral Therapy. (29th July 2014)
- Main Title:
- HIV-1 DNA Decay Dynamics in Blood During More Than a Decade of Suppressive Antiretroviral Therapy
- Authors:
- Besson, Guillaume J.
Lalama, Christina M.
Bosch, Ronald J.
Gandhi, Rajesh T.
Bedison, Margaret A.
Aga, Evgenia
Riddler, Sharon A.
McMahon, Deborah K.
Hong, Feiyu
Mellors, John W. - Abstract:
- Abstract : Total human immunodeficiency virus type 1 DNA decay plateaus after 4 years of suppressive antiretroviral therapy, and the decay rate is not associated with immune activation or residual plasma viremia. Abstract: Background. Human immunodeficiency virus type 1 (HIV-1) DNA dynamics during long-term antiretroviral therapy (ART) are not defined. Methods. Blood mononuclear cells obtained during 7–12 years of effective ART were assayed for total HIV-1 DNA and 2-long terminal repeat (LTR) circles by quantitative polymerase chain reaction (qPCR). Slopes of HIV-1 DNA were estimated by participant-specific linear regressions. Plasma was assayed for residual viremia (HIV-1 RNA) by qPCR. Results. Thirty participants were studied. HIV-1 DNA decreased significantly from years 0–1 and 1–4 of ART with median decay slopes of −0.86 (interquartile range, −1.05, −0.59) and −0.11 (−0.17, −0.06) log10 (copies/10 6 CD4+ T-cells)/year, respectively ( P < .001). Decay was not significant for years 4–7 (−0.02 [−0.06, 0.02]; P = .09) or after year 7 of ART (−0.006 [−0.030, 0.015]; P = .17). All participants had detectable HIV-1 DNA after 10 years (median 439 copies/10 6 CD4+ T-cells; range: 7–2074). Pre-ART HIV-1 DNA levels were positively associated with pre-ART HIV-1 RNA levels (Spearman = 0.71, P < .001) and with HIV-1 DNA at years 4, 7, and 10 on ART (Spearman ≥ 0.75, P < .001). No associations were found ( P ≥ .25) between HIV-1 DNA slopes or levels and % activated CD8+ T-cellsAbstract : Total human immunodeficiency virus type 1 DNA decay plateaus after 4 years of suppressive antiretroviral therapy, and the decay rate is not associated with immune activation or residual plasma viremia. Abstract: Background. Human immunodeficiency virus type 1 (HIV-1) DNA dynamics during long-term antiretroviral therapy (ART) are not defined. Methods. Blood mononuclear cells obtained during 7–12 years of effective ART were assayed for total HIV-1 DNA and 2-long terminal repeat (LTR) circles by quantitative polymerase chain reaction (qPCR). Slopes of HIV-1 DNA were estimated by participant-specific linear regressions. Plasma was assayed for residual viremia (HIV-1 RNA) by qPCR. Results. Thirty participants were studied. HIV-1 DNA decreased significantly from years 0–1 and 1–4 of ART with median decay slopes of −0.86 (interquartile range, −1.05, −0.59) and −0.11 (−0.17, −0.06) log10 (copies/10 6 CD4+ T-cells)/year, respectively ( P < .001). Decay was not significant for years 4–7 (−0.02 [−0.06, 0.02]; P = .09) or after year 7 of ART (−0.006 [−0.030, 0.015]; P = .17). All participants had detectable HIV-1 DNA after 10 years (median 439 copies/10 6 CD4+ T-cells; range: 7–2074). Pre-ART HIV-1 DNA levels were positively associated with pre-ART HIV-1 RNA levels (Spearman = 0.71, P < .001) and with HIV-1 DNA at years 4, 7, and 10 on ART (Spearman ≥ 0.75, P < .001). No associations were found ( P ≥ .25) between HIV-1 DNA slopes or levels and % activated CD8+ T-cells (average during years 1–4) or residual viremia (n = 18). 2-LTR circles were detected pre-ART in 20/29 and in 8/30 participants at last follow-up. Conclusions. Decay of HIV-1 DNA in blood is rapid in the first year after ART initiation (86% decline), slows during years 1–4 (23% decline/year), and subsequently plateaus. HIV-1 DNA decay is not associated with the levels of CD8+ T-cell activation or persistent viremia. The determinants of stable HIV-1 DNA persistence require further elucidation. Clinical Trials Registration. NCT00001137. … (more)
- Is Part Of:
- Clinical infectious diseases. Volume 59:Number 9(2014:May 01)
- Journal:
- Clinical infectious diseases
- Issue:
- Volume 59:Number 9(2014:May 01)
- Issue Display:
- Volume 59, Issue 9 (2014)
- Year:
- 2014
- Volume:
- 59
- Issue:
- 9
- Issue Sort Value:
- 2014-0059-0009-0000
- Page Start:
- 1312
- Page End:
- 1321
- Publication Date:
- 2014-07-29
- Subjects:
- HIV-1 persistence -- antiretroviral therapy; HIV-1 DNA decay -- immune activation
Communicable diseases -- Periodicals
616.905 - Journal URLs:
- http://cid.oxfordjournals.org ↗
http://ukcatalogue.oup.com/ ↗
http://www.journals.uchicago.edu/CID/journal ↗
http://www.jstor.org/journals/10584838.html ↗ - DOI:
- 10.1093/cid/ciu585 ↗
- Languages:
- English
- ISSNs:
- 1058-4838
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.293860
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21203.xml